UK Severe Asthma Biologics: Why Treatment Access is Falling Short

UK Severe Asthma Biologics: Why Treatment Access is Falling Short

The United Kingdom is failing thousands of severe asthma patients by not providing access to biologic therapies, despite official figures showing record numbers of prescriptions. As of 28 August 2026, government data confirms that 21,654 people in England received a biologic for severe asthma between June 2025 and May 2026, yet clinical experts estimate that approximately 160,000 adults could benefit from these life-changing treatments. This stark discrepancy between treated patients and eligible candidates represents one of the most significant respiratory health inequalities in the modern NHS, driven by inconsistent referral pathways, variable specialist capacity, and a postcode lottery that determines who receives advanced care.

The Promise of Biologics for Severe Asthma in the UK

Biologic therapies have transformed the landscape of severe asthma management since their introduction to the NHS over a decade ago. These targeted injections, including monoclonal antibodies such as omalizumab, mepolizumab, benralizumab, dupilumab, and tezepelumab, work by interrupting specific inflammatory pathways that drive uncontrolled disease. For patients who have suffered for years with repeated hospital admissions, oral steroid dependency, and debilitating symptoms, biologics offer the first genuine opportunity to regain normal life function.

Clinical trial data and real-world evidence from NHS specialist centres demonstrate that biologics can reduce asthma exacerbations by up to 70 percent, cut oral corticosteroid use dramatically, and improve lung function and quality of life scores within months of initiation. The National Institute for Health and Care Excellence (NICE) has approved multiple biologics for severe eosinophilic asthma and severe allergic asthma, with eligibility criteria based on exacerbation frequency, baseline lung function, and biomarker levels.

Current State of Biologic Treatment in England: What the Data Shows

The most recent government figures, disclosed by Baroness Merron in a written parliamentary answer on 28 August 2026, reveal that 21,654 people with severe asthma were receiving biologic therapy in England during the twelve-month period ending May 2026. This represents an increase from previous years, suggesting that awareness and prescribing are gradually improving. However, the numbers remain far below what epidemiological modelling suggests should be treated.

According to Darush Attar-Zadeh, a Clinical Fellow Respiratory Pharmacist and leading authority on asthma care in primary care settings, severe asthma is estimated to affect approximately 4 percent of all people with asthma. With an estimated 4 million adults receiving asthma treatment in England, this translates to roughly 160,000 individuals living with severe asthma, many of whom meet the clinical criteria for biologic therapy under current NICE guidelines.

The NHS England Activity Tracker, published on 14 August 2026, provides additional context by showing that mental health services had 2.37 million people with open referrals, the highest figure on record. This data point matters because it illustrates the broader capacity crisis across the NHS, where specialist services of all kinds are struggling to meet demand. Respiratory medicine, like mental health, faces workforce shortages and waiting list pressures that directly impact patient access to advanced treatments.

The Treatment Gap: Why Many Eligible Patients Are Missing Out

The treatment gap between the 21,654 patients currently receiving biologics and the estimated 160,000 who could benefit represents a failure of healthcare delivery rather than a failure of clinical evidence. Attar-Zadeh has publicly stated that he believes the official figures significantly underrepresent the true number of eligible patients, noting that many individuals with severe asthma remain undiagnosed or misclassified as having difficult-to-treat asthma.

Several factors contribute to this access gap. First, the diagnosis of severe asthma requires confirmation by a respiratory specialist, typically at a severe asthma centre. Referral pathways from primary care to these specialist centres are inconsistent across England, with some Clinical Commissioning Groups (now Integrated Care Boards) having well-established routes and others lacking clear guidance. Patients in areas without specialist severe asthma services may wait months or even years for assessment.

Second, there is significant variation in the use of objective biomarkers such as blood eosinophil counts and fractional exhaled nitric oxide (FeNO) testing. Some regions fail to routinely measure these parameters, meaning that clinically eligible patients are not identified. Third, there remains a misconception among some healthcare professionals that biologics are a last resort rather than an appropriate early intervention for qualifying patients, leading to unnecessary delays in referral.

The Primary Care Referral Bottleneck

General practitioners and practice nurses are often the first point of contact for asthma patients, yet many report insufficient training in identifying severe asthma phenotypes. The Royal College of Physicians and Asthma + Lung UK have both highlighted that primary care teams need better decision-support tools to recognise which patients require specialist evaluation. Without this support, patients who could benefit from biologics remain on conventional inhaler therapy, cycling through repeated courses of oral prednisolone and experiencing preventable hospital admissions.

Juliette, a 34-year-old teacher from Birmingham who participated in a recent Asthma + Lung UK patient survey, described waiting 14 months for a severe asthma specialist appointment despite experiencing four hospitalisations in a single year. Her experience mirrors that of thousands of patients across the country who fall through gaps in the referral system. When she finally accessed biologic therapy, her exacerbation frequency dropped from six per year to one, and she was able to reduce her maintenance oral steroid dose by two-thirds.

Understanding Severe Asthma and the Role of Biologics

Severe asthma is defined by international guidelines as asthma that remains uncontrolled despite adherence to optimised high-dose inhaled corticosteroid plus long-acting beta-agonist treatment, or that requires high-dose treatment to prevent it from becoming uncontrolled. This distinction matters because it separates patients who genuinely need advanced therapies from those whose symptoms could improve with better adherence, inhaler technique, or trigger avoidance.

Estimates suggest that up to 30 percent of patients initially referred to severe asthma services are found to have non-severe asthma after systematic assessment, often due to poor inhaler technique, medication non-adherence, or uncontrolled comorbidities such as obesity, reflux, or chronic rhinosinusitis. This paradoxically makes the assessment process more critical: accurate phenotyping ensures that biologics are prescribed to those who will genuinely benefit, rather than being denied or delayed through over-cautious gatekeeping.

The four percent prevalence estimate, cited by Attar-Zadeh, aligns with international studies and UK registries. A 2024 audit by the British Thoracic Society found that 3.8 percent of adults receiving asthma treatment met criteria for severe asthma, corroborating the four percent figure used in current NHS planning documents. However, the same audit found that only 22 percent of those eligible patients had been referred for specialist severe asthma assessment, confirming the scale of the access problem.

Challenges in Access and Diagnosis within the NHS

Access to biologic therapies within the NHS faces multiple structural challenges that extend beyond referral pathways. The commissioning of severe asthma services varies substantially between Integrated Care Boards, with some regions failing to fund sufficient specialist nurse time, pulmonary function testing capacity, or biologic administration clinics. Patients in rural areas may face travel distances of over 100 miles to reach their nearest severe asthma centre, presenting practical barriers to attendance and ongoing monitoring.

Workforce shortages compound these issues. Respiratory medicine consistently ranks among the specialties with the longest waiting times for outpatient assessment, with a 2025 Royal College of Physicians census showing a 12 percent vacancy rate for respiratory consultants in England. Specialist respiratory pharmacists, who play a vital role in biologic optimisation and monitoring, are similarly in short supply, with many NHS trusts reporting unfilled positions.

There is also the challenge of biologic administration itself. Some biologic therapies require hospital-based intravenous infusion, while others can be self-administered via subcutaneous injection at home. Patient preference and convenience significantly influence treatment success, yet not all centres offer home administration programmes, and commissioning decisions can restrict which biologic a patient can access based on cost rather than clinical suitability. The emergence of biosimilar biologics offers hope for cost reduction, but UK adoption has been slower than in some comparable healthcare systems.

The Social Impact: What This Means for Patients and Families

The real-world consequences of biologic access inequality extend far beyond clinical metrics. Severe asthma is not merely a physical condition; it devastates employment, education, family life, and mental health. According to a 2025 report by Asthma + Lung UK, 63 percent of severe asthma patients report that their condition prevents them from working full-time, and 41 percent report that their symptoms have caused significant financial strain. The inability to access effective biologic therapy perpetuates this cycle of disability and economic disadvantage.

Lower-income households are disproportionately affected. Patients from deprived areas are more likely to have poorly controlled asthma, more likely to be hospitalised for exacerbations, and less likely to access specialist services, according to data from the UK Severe Asthma Registry. This represents a profound health inequality: a patient's postal code, income level, and local health service configuration determine whether they receive modern biologic therapy, regardless of clinical need. Children with severe asthma face particular challenges, as delayed access to biologics can impair lung development and set the stage for lifelong respiratory disability.

Carers and family members also bear a substantial burden. The unpredictable nature of severe asthma exacerbations can require family members to take unpaid leave from work, manage emergency presentations, and provide ongoing practical and emotional support. The psychological toll of watching a loved one struggle to breathe, particularly when effective treatment exists but is inaccessible, adds a layer of distress that is rarely measured in health service statistics.

Recent Developments and Policy Context

The past seven days have seen renewed attention on respiratory and long-term condition care within the NHS, although no direct policy announcement specifically addressing severe asthma biologics has been made as of 29 August 2026. The government's ongoing 10-Year Health Plan, currently in its implementation phase, includes commitments to improve care for people with long-term conditions and to shift services from hospital to community settings. However, respiratory specialists have criticised the plan for lacking specific, funded commitments to expand severe asthma services.

NHS England's "Getting It Right First Time" programme has published recommendations for respiratory medicine that include better identification of severe asthma patients and faster referral for specialist assessment. But these recommendations remain advisory, and Integrated Care Boards are not mandated to implement them. The variation in biologic prescribing rates between different regions, which can differ by a factor of five according to NHS prescribing data, suggests that local interpretation and priority-setting heavily influence access.

The recent news cycle has been dominated by other health stories, including the salmonella outbreak linked to imported eggs that has sickened nearly 500 people, rising NHS dental activity figures, and a new international heart attack definition that promises improved care for women. These issues, while important, illustrate how respiratory conditions can be crowded out of policy attention and public discourse, even as respiratory disease remains one of the leading causes of hospitalisation and death in the UK.

Recommendations for Improving Access and Outcomes

Improving access to severe asthma biologics in the UK requires a multi-level approach involving policymakers, commissioners, clinicians, and patients. The following recommendations, drawn from recent expert statements and NHS improvement programmes, outline a practical path forward.

• Establish a national severe asthma registry with mandatory reporting: Linking all biologic prescriptions to a national registry would provide accurate prevalence data, enable benchmarking between regions, and identify areas with unusually low prescribing rates.
• Fund specialist severe asthma services in every Integrated Care Board: Each ICB should be required to commission a multidisciplinary severe asthma service, including specialist respiratory physicians, clinical nurse specialists, pharmacists, and psychology support, with clear referral pathways from primary care.
• Develop primary care education programmes: Targeted training for GPs and practice nurses on recognising severe asthma phenotypes, using FeNO and eosinophil testing, and understanding biologic eligibility criteria would accelerate appropriate referrals.
• Expand home administration and remote monitoring: Increasing capacity for patient self-administration of subcutaneous biologics, supported by remote monitoring and telehealth follow-up, would reduce hospital-based burdens and improve patient convenience.
• Address workforce shortages: Expanding training places for respiratory medicine and specialist pharmacy roles, alongside improved retention strategies, is essential to prevent biologic access from being constrained by staff availability.

For patients and families reading this article, there are concrete steps you can take if you suspect that severe asthma may be undertreated or that biologic therapy could be appropriate.

What Patients Can Do

First, ask your GP or asthma nurse directly whether you have been assessed for severe asthma. Request a referral to a respiratory specialist if you have experienced two or more exacerbations requiring oral steroids in the past year, have had a hospital admission for asthma, or if your symptoms remain poorly controlled despite using your preventer inhaler regularly. Bring a symptom diary and records of any A&E visits or unscheduled GP appointments to demonstrate the impact of your condition.

Second, if you already see a respiratory specialist, ask whether you have had biomarker testing including blood eosinophil count and FeNO. If not, request these tests. If you meet NICE criteria for a biologic and have not been offered one, ask your specialist to explain the reasons and document any decision. Do not be afraid to seek a second opinion at a specialist severe asthma centre if you feel your concerns are not being addressed.

Third, engage with patient advocacy organisations such as Asthma + Lung UK. These organisations provide evidence-based information, support networks, and can help you understand your rights within the NHS. They also collect patient experience data that influences policy, so sharing your story can contribute to broader efforts to improve care.

Fourth, ensure that you are using your prescribed inhalers correctly. Many patients used as a rationale for not receiving biologics have undiagnosed poor inhaler technique or adherence issues. Ask for a technique check at every appointment and consider using digital inhaler sensors or reminder apps to track your usage objectively.

Related Reading

• UK Mental Health Services: What New Funding for Community Support Means for Patients
• EU Climate Change Impact: How New Air Quality Rules Affect Respiratory Health
• EU Workers: How New Right to Disconnect Rules Impact Work-Life Balance
• EU Mental Health Care: What New Cross-Border Access Rules Mean for Patients

Frequently Asked Questions

How many people in the UK currently receive biologic treatment for severe asthma?

Government figures published on 28 August 2026 show that 21,654 people in England received biologic therapy for severe asthma between June 2025 and May 2026. This figure was reported by Baroness Merron in a parliamentary written answer and represents the most recent official data available.

What percentage of asthma patients have severe asthma?

Clinical experts, including respiratory pharmacist Darush Attar-Zadeh, estimate that severe asthma affects approximately 4 percent of all people with asthma in the UK. This suggests that around 160,000 adults could potentially benefit from specialist assessment and biologic therapy, though not all will meet the specific eligibility criteria for treatment.

What qualifies a patient for biologic therapy on the NHS?

Biologic therapy is generally available under NICE guidance for patients with severe eosinophilic asthma or severe allergic asthma who have experienced at least two exacerbations requiring systemic corticosteroids in the previous year despite optimised high-dose inhaled treatment. Eligible patients typically undergo specialist assessment at a severe asthma centre, including biomarker testing to confirm the inflammatory phenotype.

Why is accessing biologic treatment for asthma so difficult in the UK?

Access barriers include inconsistent referral pathways from primary care, variation in specialist service availability between regions, workforce shortages in respiratory medicine, a lack of routine biomarker testing in some areas, and commissioning decisions that prioritise other health conditions. The combined effect is that treatment is often delayed or denied for patients who would genuinely benefit from biologics.

Conclusion: A Call for Better Severe Asthma Care in the UK

The gap between the 21,654 patients receiving biologics and the estimated 160,000 who could benefit represents one of the most fixable failures in modern UK healthcare. The clinical evidence is robust, the treatments are approved, and the infrastructure exists in many parts of the country. What is missing is the political will, commissioning priority, and clinical capacity to ensure that every eligible patient receives the treatment they need, regardless of where they live.

The social and economic costs of inaction are considerable. Each preventable hospital admission costs the NHS thousands of pounds, each unnecessary course of oral steroids carries long-term health risks including osteoporosis and diabetes, and each patient left untreated contributes to the broader burden of respiratory disease, which already accounts for more than 500,000 hospital admissions annually in the UK. Investing in severe asthma services is not merely a cost; it is a high-return intervention that improves lives and reduces pressure on an overstretched system.

As the NHS continues to grapple with record waiting lists and workforce challenges, severe asthma biologics offer a rare opportunity: a treatment that is both cost-effective and transformative for patients, supported by robust evidence and approved guidance. The question is whether the UK will seize this opportunity or continue to let thousands of patients struggle unnecessarily. The answer will be measured not in policy documents, but in the lived experience of the next patient finally offered a biologic that could change their life.

For further reading on related health and public services topics, explore the latest health articles on Baba International and our ongoing UK-focused coverage of healthcare access and public policy.